Functional Fluidics Cell Biomarkers May Prove to be Effective Surrogate Endpoints for Sickle Cell
- Admin
- Feb 21, 2022
- 1 min read
Functional Fluidics officially announced the publication of its two-year study, demonstrating that its red blood cell (RBC) health biomarkers can identify individuals with sickle cell disease at greatest risk for more severe outcomes. Further research is needed to determine the clinical value of stratifying patients according to these RBC health biomarkers. Assessing RBC health could help healthcare providers identify patients at risk for severe disease outcomes so that they can intervene earlier. Functional Fluidics is a diagnostics company striving to be the gold standard for red blood cell health.
Comments